Nuwellis, a Minnesota medical device maker most investors have never heard of, was up 123.33% Thursday afternoon. That’s not a typo, and it’s not even the stock’s biggest one-day pop this month.
Shares of the microcap ultrafiltration company traded at $4.21 as of 1:06 p.m. EDT, up $2.32 from Wednesday’s close of $1.89, according to a real-time Nasdaq quote. The move came on volume of roughly 103.9 million shares against a 30-day average of about 279,330, well over 300 times normal turnover for a stock with an intraday market cap near $390,000.
The broader tape told a calmer, still-eventful story. The Nasdaq Composite led the major indexes higher, jumping 2.58% to 25,072.78, according to Yahoo Finance, a day after the Nasdaq-100 entered a technical correction on heavy chip-stock declines. The Dow and S&P 500 also advanced, per Trading Economics. The rebound followed a Wednesday session in which the Dow closed 2.19% lower at 51,594.14 for its worst day since April 2025, according to CNBC, as the bond market reacted poorly to the Fed’s decision to hold rates steady.
| Index | Level | Change | % Change |
|---|---|---|---|
| Dow Jones Industrial Average | 52,122.41 | +528.27 | +1.02% |
| S&P 500 | not independently confirmed | not independently confirmed | +1.2% to +1.45%* |
| Nasdaq Composite | 25,072.78 | +629.84 | +2.58% |
| Russell 2000 | 2,931.23 | +24.92 | +0.86% |
| VIX | 18.10 | -2.56 | -12.37% |
*S&P 500 percentage figures ranged from +1.2% to +1.45% across sources fetched at slightly different points in the session; the index level itself was not independently confirmed and is omitted rather than estimated.
Two mega-cap earnings reports drove the tech rally. Microsoft’s stock jumped after its Azure cloud business topped $100 billion in revenue for the first time, a milestone that pulled the rest of the sector higher. Meta moved the opposite direction, with shares falling after the company’s earnings miss added to worries about its ability to recoup AI investments. By early afternoon, Yahoo Finance data showed Meta down more than 9% while Microsoft was up over 16%, a split verdict on the same AI capital-spending story investors have been fighting over for months.
Treasury yields stayed a live pressure point. The 30-year Treasury yield pushed to a multidecade high near 5.24% Thursday, extending Wednesday’s bond-market response to the Fed’s hold. Fresh U.S. strikes on Iranian targets overnight, detailed by Yahoo Finance, added another layer of geopolitical risk even as oil prices held roughly flat Thursday morning.
Why Nuwellis Stock Doubled, and Then Some
Back to the single-name story of the day. Nuwellis makes the Aquadex SmartFlow system, a device that pulls excess fluid from patients whose kidneys can’t do it on their own, used in intensive care units for both adults and children. It is not a company that typically moves the market. On Thursday, three separate pieces of news collided at once.
First, Nuwellis said on July 27 that it expects preliminary second-quarter 2026 revenue growth of 14% year over year, with first-half revenue growth of 20%, ahead of full results due August 13. Second, the company disclosed a new U.S. patent tied to its ultrafiltration and continuous renal replacement therapy platform. Third, and probably the biggest single catalyst, Nuwellis announced that a new study on the drug epoprostenol as an anticoagulant during Aquadex therapy in critically ill pediatric patients was accepted into the peer-reviewed journal Frontiers in Pediatrics.
None of that alone explains a move north of 100%. The mechanism does. According to QuiverQuant, Nuwellis recently completed a 1-for-35 reverse stock split, which tightened its effective share count, a structural change that can turn ordinary buying interest into outsized percentage swings since far fewer shares need to change hands to move the price. Analysts tracking the stock have flagged the setup explicitly as a low-float squeeze rather than a fundamentals repricing.
| Metric | Value |
|---|---|
| Price | $4.2099 |
| Change | +$2.3199 (+123.33%) |
| Day Range | $3.8100 – $6.3999 |
| 52-Week Range | $1.8300 – $378.3500 |
| Volume / Avg. Volume | 103,874,720 / 279,330 |
| Market Cap (intraday) | $390,471 |
| Earnings Date | Aug. 13, 2026 |
Worth sitting with for a second: Thursday’s intraday high of $6.40 is still more than 98% below the stock’s 52-week high of $378.35. The stock has fallen roughly 99% over the trailing 12 months. A 100%-plus single-day rally on a name that’s lost nearly everything of its value over the past year is a volatility story first, and a turnaround story a distant second, if at all.
None of the three catalysts, taken alone, is a proof point for the company’s commercial prospects. The pediatric study was explicitly described by its own authors as a feasibility report, not evidence of superiority over existing treatment. Investors piling in on the peer-reviewed-journal headline alone are reacting to a real but narrow clinical milestone, not a change in the company’s underlying revenue trajectory.
What’s Next
Amazon reports earnings after Thursday’s close, with investors watching AWS growth against the same AI capital-spending scrutiny that just split Microsoft and Meta in opposite directions. Apple follows shortly after. On the macro side, June’s Personal Consumption Expenditures inflation reading and second-quarter GDP data were both on Thursday’s calendar, either of which could move the rate-cut conversation that’s been driving the bond market all week.
For Nuwellis specifically, the next scheduled catalyst is its own: full second-quarter results on August 13, when the preliminary 14% revenue growth figure either holds up or doesn’t.
This article is for informational purposes only and does not constitute financial advice.
